^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Nanoxel M (docetaxel polymeric micelle)

    i
    Other names: B 5704, SYP-0704A
    Associations

    News

    Trials
    Company:
    Samyang Group
    Drug class:
    Tubulin polymerization promoter, Microtubule stabilizer
    Related drugs:
    Associations

    News

    Trials
    6ms
    Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer (clinicaltrials.gov)
    P3, N=26, Terminated, Samyang Biopharmaceuticals Corporation | N=320 --> 26 | Trial completion date: Dec 2024 --> May 2024 | Recruiting --> Terminated; The Decision to Terminate Early Due to Difficulties in Recruiting Participants and Conducting the Study.
    Enrollment change • Trial completion date • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative
    |
    cyclophosphamide • Nanoxel M (docetaxel polymeric micelle)
    9ms
    Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer (clinicaltrials.gov)
    P3, N=320, Recruiting, Samyang Biopharmaceuticals Corporation | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2023 --> Mar 2024
    Enrollment open • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative
    |
    cyclophosphamide • Nanoxel M (docetaxel polymeric micelle)
    over1year
    A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. (PubMed, Cancer)
    Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. SDC shares morphological and histological similarities with invasive ductal carcinoma of breast, which led to an investigation of hormonal receptor and human epidermal growth factor receptor 2 (HER2)/neu expression status in SDC. In this study, patients with HER2-positive SDC were enrolled and treated with combination of docetaxel-polymeric micelle and trastuzumab-pkrb. Promising antitumor activities were shown with objective response rate of 69.8%, disease control rate of 93.0%, median progression-free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months.
    Clinical • P2 data • Journal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herzuma (trastuzumab-pkrb) • Nanoxel M (docetaxel polymeric micelle) • SIBP-01 (trastuzumab biosimilar)
    almost3years
    Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer (clinicaltrials.gov)
    P3, N=320, Not yet recruiting, Samyang Biopharmaceuticals Corporation
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative
    |
    doxorubicin hydrochloride • cyclophosphamide • Nanoxel M (docetaxel polymeric micelle)